Macular Degeneration Trial, Recruiting (NCT04571658)

Macular Degeneration Trial, Recruiting NCT04571658 Sponsor: University of Michigan Condition: Macular Degeneration

Printed from Voxsanity (voxsanity.com.au) — NCT04571658 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Macular Degeneration

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are already enrolled in a related research study called NEPTUNE (either in the group that had a kidney biopsy or the group that did not).
People who meet the eligibility requirements for at least one of the partnering clinical trials linked to this study — note that these partnering trials and their requirements may change over time (confirm with trial site).
People who receive regular kidney specialist (nephrology) care at a hospital or clinic that is part of the NEPTUNE study network.
People who are willing and able to give their consent to take part, and where relevant (for younger participants), also give their assent.

Who may not be able to join:

People who are not already enrolled in the NEPTUNE observational study.
People whose primary language is not English or Spanish.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Matthias Kretzler, MD, University of Michigan

Phone: 734-232-4851

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04571658

Sponsor: University of Michigan

Phase: Not Applicable

Status: Recruiting

Condition: Macular Degeneration

Trial contact: 734-232-4851

More information: https://clinicaltrials.gov/study/NCT04571658

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are already enrolled in a related research study called NEPTUNE (either in the group that had a kidney biopsy or the group that did not).
People who meet the eligibility requirements for at least one of the partnering clinical trials linked to this study — note that these partnering trials and their requirements may change over time (confirm with trial site).
People who receive regular kidney specialist (nephrology) care at a hospital or clinic that is part of the NEPTUNE study network.
People who are willing and able to give their consent to take part, and where relevant (for younger participants), also give their assent.

Who may not be able to join:

People who are not already enrolled in the NEPTUNE observational study.
People whose primary language is not English or Spanish.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Michigan

Registry

ClinicalTrials.gov

Start date

2 May 2022

Est. completion

30 December 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Matched participants with at least one clinical trial receive a MNB assessment; Efficacy of communication methods at time of communication visit, measured by Teach Back 1 summary score; Kidney health endpoints that are specific to each individual trial

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov